Sanofi reviews

The reorganization was difficult and led to many established connections to fall apart. Training and development is needed during a reorganization to nail what is expected.

Some Sr Managers from the early days got there by luck and not competence. Poor resource allocation. Too much cash spent on lousy acquisitions that never paid off. That diverted resources away from securing the sustainability of the core business, which was rare diseases. Unfortunately the result was a large drop on the share price, opening the door to activist investors that ultimately sold it to Big Pharma. A pity in my view.